StocksMedium•4 November 2026•
1 min read
Egetis Therapeutics to Sell Priority Review Voucher for $190 Million
Key Facts
1Egetis Therapeutics entered a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher for $190 million.
Egetis Therapeutics entered a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher for $190 million. Benzinga reported that the sale allows the company to monetize the regulatory asset for gross proceeds.
The transaction generates significant non-dilutive capital for the biotechnology firm, strengthening its liquidity position. The identity of the buyer remained undisclosed in the announcement made on November 4, 2026.